Matinas Biopharma Holdings, Inc. (MTNB): Price and Financial Metrics

Matinas Biopharma Holdings, Inc. (MTNB): $0.75

0.00 (0.00%)

POWR Rating

Component Grades













Add MTNB to Watchlist
Sign Up

Industry: Biotech



in industry

MTNB Stock Price Chart Interactive Chart >

Price chart for MTNB

MTNB Price/Volume Stats

Current price $0.75 52-week high $1.61
Prev. close $0.75 52-week low $0.49
Day low $0.74 Volume 213,100
Day high $0.78 Avg. volume 682,709
50-day MA $0.76 Dividend yield N/A
200-day MA $0.89 Market Cap 162.65M

Matinas Biopharma Holdings, Inc. (MTNB) Company Bio

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections.

MTNB Latest News Stream

Event/Time News Detail
Loading, please wait...

MTNB Latest Social Stream

Loading social stream, please wait...

View Full MTNB Social Stream

Latest MTNB News From Around the Web

Below are the latest news stories about Matinas BioPharma Holdings Inc that investors may wish to consider to help them evaluate MTNB as an investment opportunity.

Matinas BioPharma Provides Business Update and 2022 Strategic Outlook

– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Topline Interim Data Expected Q3 2022 – – In Vivo Study of Orally Administered LNC Remdesivir Demonstrated Reduced Viral Titers and Effects Similar to Subcutaneous Administered Remdesivir; NIAID to Support an Additional Preclin

Yahoo | January 25, 2022

Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022

Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ETBEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Tuesday, January 25, 2022 at 8:30 a.

Yahoo | January 18, 2022

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

– DSMB evaluated both safety and efficacy data in recommending cohort progression –

Intrado Digital Media | December 16, 2021

Analysts Predicting A Spike In Matinas BioPharma Holdings Inc. (AMEX: MTNB)?

Matinas BioPharma Holdings Inc. (AMEX:MTNB) price on Wednesday, December 08, rose 9.90% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.11. A look at the stock’s price movement, the close in the last trading session was $1.01, moving within a range at $1.01 and $1.16. The beta … Analysts Predicting A Spike In Matinas BioPharma Holdings Inc. (AMEX: MTNB)? Read More »

Stocks Register | December 9, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 8, 2021

Read More 'MTNB' Stories Here

MTNB Price Returns

1-mo 6.38%
3-mo 30.62%
6-mo -28.57%
1-year -2.60%
3-year -21.88%
5-year -71.80%
YTD -25.74%
2021 -25.74%
2020 -40.09%
2019 281.51%
2018 -48.71%
2017 -17.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7283 seconds.